Industry sponsored studies twice as likely to have positive conclusions about costs

BMJ 2003; 327 doi: (Published 30 October 2003) Cite this as: BMJ 2003;327:1006
  1. Roger Dobson
  1. Abergavenny

    Researchers have warned of the risk of sponsorship bias in health economic studies in the field of cancer.

    Industry sponsored studies were twice as likely to be cost minimisation analyses, which compare equally effective treatments on the basis of costs. The industry studies were 2.5 times …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription